Effect of polymorphic CYP2C19 genotype on the pharmacokinetics and pharmacodynamics of clopidogrel in healthy subjects

Not Applicable

Completed

• Conditions: Cardiovascular diseases; Circulatory System

• Registration Number: ISRCTN39669611
• Lead Sponsor: Korea University (South Korea)

Brief Summary

2008 results in: https://www.ncbi.nlm.nih.gov/pubmed/18323861 (added 24/05/2019)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2007-08-31
• Study Start: 2007-09-17
• Last Update Posted: 17 June 2019

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 24

Inclusion Criteria

1. Healthy male subjects aged between 19 to 55
2. Wish to participate in the study
3. Informed consent for the trial

Exclusion Criteria

1. A history of or currently active clinically significant cardiac (including clinically significant abnormalities on Electrocardiogram [ECG] according to Principal Investigator [PI]), pulmonary, gastrointestinal, hepatic, renal, pancreatic, or neurological disease
2. Heavy smoker and alcohol consumer
3. Use of anticoagulants or medication within the last 1 month

Study & Design

• Study Type: Interventional
• Study Design: Not specified